glp-1 agonist weight gain effects Study finds receptor agonists target fat over muscle for loss Frontiers | Exploring the multifaceted
Description
However, recent Phase III data for the trifunctional GLP-1/GIP/Glucagon receptor agonist retatrutide show average weight loss of around 28.7%, significantly exceeding results from GLP-1 monotherapy
6 (2013): 10251034, 10.4158/EP12306.RA
Fasting insulin levels, HOMA-IR (a measure of insulin resistance), high-sensitivity C-reactive protein (an inflammation marker), liver enzymes (indicators of fatty liver disease), and advanced lipid panels all provide evidence of metabolic dysfunction that weight alone cannot capture
10.1136/bmj.l4898 38 SunF.WuS.GuoS.YuK.YangZ.LiL.et al (2015)
